[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"methamphetamine-dependence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:methamphetamine-dependence":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,65,99,129,154,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100608645","phase-2-glutide-for-ending-methamphetamine-100608645",false,"NCT07204249","Glutide for Ending Methamphetamine","GEM","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Ability to provide informed consent before any study-related activity, willing to comply with all study procedures, and be available for the duration of the study,\n2. Age 18 - 65 years inclusive,\n3. Moderate to severe Methamphetamine Use Disorder by Structured Clinical Interview for DSM Disorders (SCID),\n4. Self-reported methamphetamine use ≥15 days out of the past 30,\n5. Methamphetamine-positive urine during screening and run-in period,\n6. Interested in stopping or reducing meth use,\n7. BMI ≥ 25kg\u002Fm2,\n8. Have at least 1 centimeter of scalp hair,\n9. Agree (if the participant is of child-bearing potential) to use effective contraceptive methods, unless all of the participant's male partner(s) is\u002Fare surgically sterile (underwent vasectomy). Acceptable contraceptives include oral contraceptives, contraceptive sponge, patch, double barrier (diaphragm\u002Fspermicidal or condom\u002Fspermicidal), intrauterine contraceptive system, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse, and\u002For hormonal vaginal ring. Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use. Women of child-bearing potential must provide negative urine pregnancy test prior to randomization.\n\n   Note: A woman is considered fertile (of childbearing potential) following menarche and until becoming postmenopausal unless permanently sterile. Women in the following categories are not considered of childbearing potential: premenarcheal, premenopausal female with one of the following: documented hysterectomy, documented bilateral salpingectomy, documented bilateral oophorectomy. Postmenopausal female is defined as no menses for 12 months without an alternative medical cause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the trial.\n10. Be able to provide the names of at least 2 persons who can consistently locate their whereabouts.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Uncontrolled hypertension or systolic BP \\>160 mmHg and\u002For diastolic BP \\>90 mmHg, averaged from three measurements,\n2. Diabetes (type 1 or 2), hemoglobin A1c ≥ 6.5 at screening, or history of diabetic ketoacidosis,\n3. History or current hypoglycemia (blood glucose \\\u003C70 mg\u002FdL),\n4. History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.\n5. History of heart failure or severe gastrointestinal disease (including acute or chronic pancreatitis, any gastric emptying disorder, gallbladder disease; any gastric resection),\n6. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B,\n7. Impaired renal function (estimated GFR \\\u003C60 ml\u002Fmin),\n8. Lipase, amylase, direct (conjugated) bilirubin, or alkaline phosphatase (ALP) 1.5 times the upper limit of normal, or ALT or AST more than 2.5 times the upper limit of normal,\n9. Calcitonin value equal to or above 50 ng\u002FL,\n10. History of retinopathy,\n11. Women who are currently pregnant, or plan to become pregnant, or lactating, or of childbearing potential and are not using medically accepted forms of contraception (see inclusion criterion 9 regarding medically accepted forms of contraception).\n12. Acute or chronic illnesses likely to result in hospitalization or death during trial participation,\n13. Plan to have all hair removed or chemically treat hair during study,\n\nPsychiatric\u002FSubstance Use Exclusions:\n\n1. Moderate to severe opioid, cocaine, or alcohol use disorder,\n2. Current non-drug-induced psychotic disorder by Structured Clinical Interview for DSM Disorders (SCID),\n3. History of a suicide attempt or past 30-day suicidal ideation,\n4. Have any psychiatric illness or condition which in the opinion of the PI and\u002For the Study Physician would preclude safe and\u002For successful completion of the study,\n\nWeight-related exclusions:\n\n1\\. Uncontrolled thyroid disease,\n\nMedication-related exclusions:\n\n1. Past 30 day use of sulfonylureas, insulin and insulin products, or medication used for weight management (e.g., orlistat, naltrexone-bupropion, liraglutide, semaglutide, tirzepatide, phentermine, topiramate, benzhetamine, diethylpropion, phendimetrazine).\n2. Prior use of or known hypersensitivity to any GLP-1 agonist,\n3. Any otherwise not specified concomitant medication that could compromise participant safety or treatment in the opinion of the Study Physician and\u002For the PIs,\n\nGeneral exclusions:\n\n1. Current, anticipated, or pending enrollment in another addiction treatment program and\u002For research study that could potentially affect participant safety and\u002For the study data\u002Fdesign as determined by the Principal Investigator and\u002For Study Physician.\n2. Planning to leave the area during the trial,\n3. Surgery scheduled during the trial, except for minor surgical procedures that, in the opinion of the PI and\u002For the Study Physician, will not require general anesthesia with the risk of aspiration,\n4. Unable to communicate (read, write, and speak) fluently in English, OR\n5. Any other condition that, in the PI's judgment, interferes with safe study participation or adherence to study procedures.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},162,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","GEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD).\n\nThe first phase is a pilot study, which will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, with a subsequent follow-up visit at week 20. This phase will evaluate the feasibility, acceptability, and preliminary efficacy of Wegovy for MeUD.\n\nThe second phase will be a phase IIb randomized-controlled trial to determine the efficacy of Wegovy in treating MeUD. This trial will be similar to the pilot with randomization to Wegovy or placebo and blinding of group assignment. The trial will enroll 162 participants across two sites.",[28],"Methamphetamine-dependence","RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-03","ACTUAL",{"date":35,"type":33},"2026-02-26",{"date":37,"type":22},"2030-02-15",{"name":39,"class":40},"San Francisco Department of Public Health","OTHER_GOV",1,{"id":43,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100534051","NCT06233799","Trial of Naltrexone\u002FBupropion for the Treatment of Methamphetamine Use Disorder","Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection\u002FBupropion XL Tablets in the Treatment of Methamphetamine Use Disorder","Inclusion Criteria:\n\n1. Is 18 to 65 years of age;\n2. Meets DSM-5 criteria for moderate or severe MUD (4 or more criteria);\n3. Is interested in reducing or stopping MA use;\n4. Is able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study;\n5. Self-reports MA use on 18 or more days in the 30-day period prior to consent using the Timeline Followback (TLFB);\n6. Provides at least 2 urine samples positive for MA out of up to 3 tests, which will occur at least 2 days apart within a 10-day period;\n7. If assigned as female at birth and\u002For currently has a uterus, is not pregnant, agrees to use acceptable birth control methods, and have periodic urine pregnancy testing done during participation in the study unless documentation of hysterectomy provided;\n8. Is not physically dependent on opioids and meets subjective and objective measures of being opioid-free prior to naltrexone injection per study medical clinician's determination, including, if clinically required, a negative naloxone challenge;\n9. Is willing to comply with all study procedures and medication instructions;\n10. Agrees to use a smartphone app (downloaded for free to own device or on a study provided smartphone device) to take daily videos of medication dosing.\n\nExclusion Criteria:\n\n1. Has an acute medical or psychiatric disorder that would, in the judgment of the study medical clinician, make participation difficult or unsafe;\n2. Has suicidal or homicidal ideation that requires immediate attention;\n3. Has a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study medical clinician;\n4. Has evidence of second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening ECG that, in the opinion of the study medical clinician, would preclude safe participation in the study;\n5. Has Stage 2 hypertension as determined by the study medical clinician (e.g., greater than or equal to 160\u002F100 in 2 out of 3 readings during screening);\n6. Has any elevated bilirubin test value per laboratory criteria OR any other liver function test (LFT) value \\> 5 times the upper limit of normal per laboratory criteria;\n7. Has a platelet count \\\u003C100 x 10exp3\u002Fmicroliter;\n8. Has a body habitus that precludes gluteal intramuscular injection of XR-NTX in accordance with the administration equipment (needle) and procedures;\n9. Has a known allergy or sensitivity to bupropion, naloxone, naltrexone, PLG (polyactideco-glycolide), carboxymethylcellulose or any other component of the XR-NTX diluents;\n10. Has been in a prior study of pharmacological or behavioral treatment for MUD within 6 months of study consent;\n11. Has taken an investigational drug in another study within 30 days of study consent;\n12. Has been prescribed and taken naltrexone or bupropion within 30 days of study consent;\n13. Is concurrently enrolled in formal behavioral or pharmacological Substance Use Disorder (SUD) treatment services;\n14. Is receiving ongoing treatment with tricyclic antidepressants, xanthines (i.e., theophylline and aminophylline), systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous system stimulants (e.g., Adderall, Ritalin, etc.), or any medication that, in the judgment of the study medical clinician, could interact adversely with study medications;\n15. Has a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study as determined by the study medical clinician;\n16. Requires treatment with opioid-containing medications (e.g., opioid analgesics) during the study period;\n17. Has a surgery planned or scheduled during the study period;\n18. Is currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that could prevent participation in the study or in any study activities;\n19. If assigned as female at birth and\u002For currently has a uterus, is currently pregnant, breastfeeding, or planning on conception.",{"count":49,"type":22},360,[51],"PHASE3","The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX\u002FBUP-XL) compared to matched injectable and oral placebo (iPLB\u002FoPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.",[28,54],"Methamphetamine Abuse",{"date":56,"type":33},"2026-06-04",{"date":58,"type":33},"2024-07-01",{"date":60,"type":22},"2027-04-30",{"name":62,"class":63},"National Institute on Drug Abuse (NIDA)","NIH",11,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100576691","phase-2-feasibility-of-long-term-high-dose-stimulant-for-methamphetamine-use-disorder-100576691","NCT06788587","Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder","Exploring Feasibility and Acceptability of Prolonged Administration of High-Dose Stimulants in People With Methamphetamine Use Disorder: An Extension of a Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Between 18 and 55 years of age at enrollment in the parent ASCME trial;\n2. Diagnosed with a moderate to severe MUD as defined by the DSM-5 criteria;\n3. Enrolled in the parent ASCME trial and completed the study up to and including the end of study visit at Week 20, Day 1;\n4. Interested in avoiding relapse, decreasing methamphetamine use, or abstaining from methamphetamine use;\n5. Presence of ongoing substance use, craving, or significant risk of relapse that according to the study physician, warrants extended treatment for MUD;\n6. If female:\n\n   * Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n   * Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;\n7. Willing to be randomized to one of 2 study arms and followed for the duration of the trial;\n8. Able to start the study intervention within 28 days after completing the ASCME main trial (study no. CRISM-002);\n9. Able to provide informed consent;\n10. Willing to comply with study procedures;\n11. Able to communicate in English or French\n\nExclusion Criteria:\n\n1. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; confirmed current hyperthyroidism; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, or unstable medical condition (including electrolyte disturbances) that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent;\n2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study;\n3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Treatment (OAT) for \\\u003C12 weeks, and not yet at stabilization dose, or at stabilization dose \\\u003C4 weeks;\n4. Current or a history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study;\n5. History of a SAE, hypersensitivity or known allergic reaction to LDX-01 or other amphetamine drugs, or hypersensitivity to the sympathomimetic amines;\n6. Pregnant, nursing, or planning to become pregnant during the study period;\n7. Planned extended absence during the study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study;\n8. Use of an investigational drug for stimulant use disorder during the 30 days before screening, confirmed via self-report or pharmacy records; excluding the use of study medication in the parent ASCME trial;\n9. Use of prescribed amphetamine-type medication or medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion, or mirtazapine) in the 4 weeks before screening;\n10. Current or anticipated need for treatment with any medication that may interact with LDX-01 (e.g., monoamine oxidase inhibitors \\[MAOIs\\]) used currently or within the past 14 days and that would preclude study participant at the discretion of the study physician;\n11. ECG measurement (Bazett method for the correction of QT interval) that indicates a prolonged QTc interval (≥460 milliseconds for females and ≥450 milliseconds for males) at screening;\n12. Any SAEs related to the study product in the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study;\n13. Any compliance issues related to the study product and\u002For study procedures during the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study.","55 Years",{"count":74,"type":22},80,[25],"Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment.\n\nThe goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group.\n\nParticipants will be placed randomly into one of two groups:\n\n1. TAU and high-dose LDX-01\n2. TAU and placebo",[54,28,78,79,80],"Addiction","Substance Abuse","Methamphetamine Use Disorder",[82,83,84,85,86,87,88],"Substance use disorder","Amphetamines","Methamphetamine","Lisdexamfetamine","Treatment","Agonist therapy","Feasibility","2026-02-19",{"date":91,"type":33},"2026-02-23",{"date":93,"type":33},"2025-07-18",{"date":95,"type":22},"2027-12",{"name":97,"class":98},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":109,"conditions":110,"keywords":116,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100433670","encouraging-abstinence-behavior-in-a-drug-epidemic-optimizing-dynamic-incentives-100433670","NCT04927143","Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives","Inclusion Criteria:\n\n* Age at least 18 years old;\n* Meet DSM-5 OUD, CoUD, or MUD criteria as evidenced by an OUD CPT code F11\\* (opioid related disorders), a CoUD CPT code F14\\* (cocaine related disorders), a MUD CPT code F15.1\u002FF15.2 or other clinical notes indicating illicit opioid\u002Fcocaine\u002Fmethamphetamine use for treatment\n* Have access to a smartphone (iOS or Android) with data plan and willing to download DynamiCare app;\n* Have an email and can access it from their smartphone;\n* Are in residential, day (PHP), partial day (IOP), or outpatient (OP) AODA treatment;\n* Are likely to be helped by contingency management because at least ONE of the following conditions is true:\n\n  1. Were first enrolled in residential, PHP, or IOP substance use treatment no longer than 2 treatment weeks (14 days\u002Fencounters of treatment) prior to providing informed consent.\n  2. Used non-medical opioids, cocaine, and\u002For methamphetamine within the last 21 days.\n* Understands English.\n\nExclusion Criteria:\n\n* Have evidence of active (non-substance related) psychosis that might impair participation as determined by the PI.\n* Has significant cognitive impairment that might confound participation as determined by the PI or are so significantly cognitively impaired that they have a legal guardian.",{"count":106,"type":22},600,[108],"NA","Combatting the rise of the opioid epidemic is a central challenge of U.S. health care policy. A promising approach for improving welfare and decreasing medical costs of people with substance abuse disorders is offering incentive payments for healthy behaviors. This approach, broadly known as \"contingency management\" in the medical literature, has repeatedly shown to be effective in treating substance abuse. However, the use of incentives by treatment facilities remains extremely low. Furthermore, it is not well understood how to design optimal incentives to treat opioid abuse. This project will conduct a randomized evaluation of two types of dynamically adjusting incentive schedules for people with opioid use disorders or cocaine use disorders: \"escalating\" schedules where incentive amounts increase with success to increase incentive power, and \"de-escalating\" schedules where incentive amounts decrease with success to improve incentive targeting. Both schemes are implemented with a novel \"turnkey\" mobile application, making them uniquely low-cost, low-hassle, and scalable. Effects will be measured on abstinence outcomes, including longest duration of abstinence and the percentage of negative drug tests. In combination with survey data, variation from the experiment will shed light on the barriers to abstinence more broadly and inform the understanding of optimal incentive design.",[111,112,113,114,115,54,28],"Opioid-use Disorder","Cocaine Use Disorder","Opioid Use","Cocaine Use","Substance Use",[117,118],"contingency management","app-based treatment","2026-02-09",{"date":121,"type":33},"2026-02-12",{"date":123,"type":33},"2021-09-15",{"date":125,"type":22},"2026-09",{"name":127,"class":98},"Wake Forest University Health Sciences",2,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100504925","phase-2-clinical-trial-of-high-dose-lisdexamfetamine-and-contingency-management-in-ma-users-100504925","NCT05854667","Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users","Addition of High Dose Stimulant and Engagement-focused Contingency Management (CM), Alone and in Combination, to Treatment as Usual (TAU) for the Management of Methamphetamine (MA) Use Disorder (ASCME): a Canadian Multi-centre, RCT","Inclusion Criteria:\n\n* Participant must meet all the following criteria:\n\n  1. Between 18 and 55 years of age;\n  2. Diagnosed with a moderate to severe methamphetamine (MA) use disorder as defined by the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria;\n  3. Active MA use at screening measured via self-reported MA use ≥14 days in the past 28 days AND verified by urine drug metabolite testing;\n  4. Interested in reducing\u002Fstopping MA use;\n  5. If female:\n\n     1. Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n     2. Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;\n  6. Willing to be randomized to one of the 4 study arms and followed for the duration of the trial;\n  7. Able to provide informed consent;\n  8. Willing to comply with study procedures;\n  9. Able to communicate in English or French.\n\nExclusion Criteria:\n\n* 1\\. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; current hyperthyroidism confirmed via blood test; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, OR unstable medical condition that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent; 2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study; 3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Therapy (OAT) for \\\u003C 12 weeks, and not yet at stabilization dose, or at stabilization dose \\\u003C 4 weeks; 4. Current or history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study; 5. History of a severe adverse event, hypersensitivity or known allergic reaction to LDX or other amphetamine drugs OR hypersensitivity to the sympathomimetic amines; 6. Pregnant, nursing, or planning to become pregnant during the study period; 7. Planned extended absence during study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study; 8. Use of an investigational drug for stimulant use disorder during the 30 days prior to screening, confirmed via self-report OR pharmacy records; 9. Currently receiving contingency management for the treatment of stimulant use disorder in the 4 weeks prior to screening, confirmed via self-report OR site records; 10. Use of prescribed amphetamine-type medication OR medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion) in the 4 weeks prior to screening; 11. Current or anticipated need for treatment with any medication that may interact with LDX (e.g., proton pump inhibitors, monoamine oxidase inhibitors \\[MAOIs\\]) used currently or within the past 14 days AND that would preclude study participant at the discretion of the study physician",{"count":137,"type":22},440,[25],"The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic.\n\nThe main questions the trial aims to answer are:\n\nIs a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine?\n\nParticipants will be placed randomly into one of four groups:\n\n1. Usual treatment and placebo\n2. Usual treatment, placebo and contingency management\n3. Usual treatment and high dose stimulant\n4. Usual treatment, high dose stimulant and contingency management\n\nParticipation includes the following:\n\n1. Participants will receive medication or placebo weekly for 15 weeks.\n2. Participants will attend the clinic for weekly treatment\n3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.",[54,28,141,78],"Addiction, Substance",[143,144],"Contingency Management","Treatment as Usual","2026-02-03",{"date":147,"type":33},"2026-02-05",{"date":149,"type":33},"2023-12-05",{"date":151,"type":22},"2028-04",{"name":97,"class":98},4,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":162,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":172,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100569995","role-of-pavlovian-mechanisms-for-control-over-substance-use-100569995","NCT06701487","Role of Pavlovian Mechanisms for Control Over Substance Use","SFB TRR 265: Losing and Regaining Control Over Drug Intake Work Package 1 of Project B03: General and Specific Pavlovian-to-Instrumental Transfer Effects in a Range of Substance Use Disorders","ReCoDe","Inclusion Criteria:\n\n* Men and women between 18-65 years of age,\n* AUD, and\u002For SUD subjects only: meet 4 or more criteria for DSM-5 alcohol-related and\u002For substance-related (cannabis, amphetamine, methamphetamine or cocaine disorder (not requiring withdrawal as assessed by an independent psychiatrist),\n* Currently using alcohol without a desire for abstinence\n* Ability to consent to the study and complete the questionnaires.\n* Sufficient language(German) and motor skills for using PC\n* existing health insurance\n\nExclusion Criteria:\n\n* Lifetime diagnosis of DSM-5 bipolar disorder or schizophrenia or schizophrenia spectrum disorder (if induced by drugs, it should happen more than a month ago)\n* Current threshold DSM-5 diagnosis of major depressive disorder, or presence of suicidal intention\n* High risk (≤ 26) ASSIST scores in other substances other than alcohol, amphetamine, methamphetamine, cannabis, cocaine, tobacco\n* History of traumatic brain injury or severe neurological disease (such as Dementia, Parkinson's disease, multiple sclerosis, Epilepsy, Meningitis, Stroke)\n* Pregnancy or breastfeeding,\n* Ingestion of medications known to interact with the dopamine system in the 10-day period prior to study participation or less than 4 half-lives after last ingestion (rapid urine test); A detailed list of permitted medication can be added upon request\n* MR contraindications (e.g., pacemakers, metallic or electronic implants, metallic splinters, surgical staples)\n* Color vision deficiency\n* sensorineural hearing loss of 30 dB or greater,\n* Tinnitus and\n* Acute alcohol, substance (cannabis, or methamphetamine, amphetamine, cocaine) intoxication at assessement day verified by breath alcohol tests and drug intoxication verified by rapid urine test.",{"count":163,"type":22},200,"OBSERVATIONAL","During the first funding period (1st FP), the investigators developed a novel full Pavlovian-to-instrumental transfer (PIT) task that allows assessing both, general and specific PIT to investigate whether specific PIT differs between alcohol use disorder (AUD) and control subjects. Preliminary analyses of the full transfer task indicate that AUD participants exhibit a stronger specific PIT effect compared to controls. Based on these findings, the investigators want to compare specific and general PIT effects in patients with moderate to severe substance use disorders (alcohol, cannabis, methamphetamine, amphetamine and cocaine) to healthy controls on the behavioral and neural level (fMRI).",[167,168,169,170,28,171,112],"Alcohol Use Disorder (AUD)","Alcoholism","Substance Use Disorders","Cannabis Use Disorder","Amphetamine Use Disorder",[173,174,80,171,112,167,175,176,177,178,179,180,181,182,183,184],"Substance Use Disorder (SUD)","Cannabise Use Disorder","Pavlovian-to-Instrumental Transfer (PIT)","General Pavlovian-to-Instrumental Transfer","Outcome-specific Pavlovian-to-Instrumental Transfer","Amygdala","Ventral Striatum","Neuroimaging","Humans","Surveys and Questionnaires","Reward","Cues","2024-11-19",{"date":187,"type":33},"2024-11-22",{"date":189,"type":33},"2024-08-05",{"date":191,"type":22},"2027-06-30",{"name":193,"class":98},"Technische Universität Dresden",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":41},"100252744","phase-3-creatine-for-depressed-male-and-female-methamphetamine-users-100252744","NCT02568878","Creatine for Depressed Male and Female Methamphetamine Users","An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users","Inclusion Criteria:\n\n* Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse\n* Current diagnosis of major depressive disorder (primary or substance-induced)\n* Current diagnosis of an anxiety disorder (primary or substance-induced)\n* Current Hamilton Depression Rating scale score \\> or = to 16\n* Current Hamilton Anxiety Scale score \\> = to 18\n* If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \\> = to 4 weeks prior to creatine treatment initiation\n\nExclusion Criteria:\n\n* Persons unable to provide adequate informed consent\n* Persons who are at clinically significant suicidal or homicidal risk\n* Primary substance-related diagnosis other than methamphetamine dependence or abuse\n* Positive pregnancy test (females only)\n* History of renal disease\n* Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing\n* History of hypersensitivity reaction to creatine","59 Years",{"count":203,"type":22},29,[51],"* Assess the antidepressant\u002Fanxiolytic effect of creatine in male and female methamphetamine users\n* Assess creatine's effect on methamphetamine use\n* Assess the safety of creatine in male methamphetamine users with depression",[207,208,209],"Depression","Anxiety","Methamphetamine Dependence",[207,208,211],"Methamphetamine dependence","2015-12-10",{"date":214,"type":22},"2015-12-11",{"date":216,"type":4},"2015-11",{"date":218,"type":22},"2017-05",{"name":220,"class":98},"Montana State University"]